Nature Communications (Jun 2018)

Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer

  • Yang Shu,
  • Weihan Zhang,
  • Qianqian Hou,
  • Linyong Zhao,
  • Shouyue Zhang,
  • Jiankang Zhou,
  • Xiaohai Song,
  • Yan Zhang,
  • Dan Jiang,
  • Xinzu Chen,
  • Peiqi Wang,
  • Xuyang Xia,
  • Fei Liao,
  • Dandan Yin,
  • Xiaolong Chen,
  • Xueyan Zhou,
  • Duyu Zhang,
  • Senlin Yin,
  • Kun Yang,
  • Jianping Liu,
  • Leilei Fu,
  • Lan Zhang,
  • Yuelan Wang,
  • Junlong Zhang,
  • Yunfei An,
  • Hua Cheng,
  • Bin Zheng,
  • Hongye Sun,
  • Yinglan Zhao,
  • Yongsheng Wang,
  • Dan Xie,
  • Liang Ouyang,
  • Ping Wang,
  • Wei Zhang,
  • Meng Qiu,
  • Xianghui Fu,
  • Lunzhi Dai,
  • Gu He,
  • Hanshuo Yang,
  • Wei Cheng,
  • Li Yang,
  • Bo Liu,
  • Weimin Li,
  • Biao Dong,
  • Zongguang Zhou,
  • Yuquan Wei,
  • Yong Peng,
  • Heng Xu,
  • Jiankun Hu

DOI
https://doi.org/10.1038/s41467-018-04907-0
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 11

Abstract

Read online

Signet-ring cell carcinoma (SRCC) is a unique type of gastric cancer with no prognostic features. Here, the authors report a CLDN18-ARHGAP26/6 gene fusion in patients with a high signet-ring cell content, poor survival outcomes, and who experience no benefit from platinum/fluoropyrimidines-based chemotherapy.